Longitudinal model–based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer

被引：0
|
作者：
Wenjun Chen
Liang Li
Shuangmin Ji
Xuyang Song
Wei Lu
Tianyan Zhou
机构：
[1] Peking University,Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences
[2] National Medical Products Administration,Center for Drug Evaluation
[3] University of Florida,Department of Pharmaceutics, College of Pharmacy
来源：
European Journal of Clinical Pharmacology | 2020年 / 76卷
关键词：
Model-based meta-analysis; Castration-resistant prostate cancer; Progression-free survival; Overall survival; Longitudinal data;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：589 / 601
页数：12
相关论文
共 50 条
  • [41] Current Status of Monoclonal Antibodies-Based Therapies in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials
    Tarrar, Talha Azam
    Anwar, Muhammad Yasir
    Ali, Muhammad Ashar
    Saeed, Memoona
    Rehman, Sana
    Bajwa, Shammas F.
    Ayub, Tooba
    Javid, Haleema
    Ali, Rimsha
    Irshad, Alaa
    Aiman, Wajeeha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (03)
  • [42] Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
    Warli, Syah Mirsya
    Velaro, Adrian Joshua
    Firsty, Naufal Nandita
    Tala, Zaimah Zulkarnaini
    WORLD JOURNAL OF ONCOLOGY, 2023, 14 (06) : 518 - 528
  • [43] Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Sahoo, Ranjit Kumar
    Dwivedi, Sada Nand
    Bal, Chandrasekhar
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2019, 213 (02) : 275 - 285
  • [44] Cabazitaxel for the treatment of castration-resistant prostate cancer
    Agarwal, Neeraj
    Sonpavde, Guru
    Sartor, Oliver
    FUTURE ONCOLOGY, 2011, 7 (01) : 15 - 24
  • [45] Visceral Disease in Castration-resistant Prostate Cancer
    Pezaro, Carmel J.
    Omlin, Aurelius
    Lorente, David
    Rodrigues, Daniel Nava
    Ferraldeschi, Roberta
    Bianchini, Diletta
    Mukherji, Deborah
    Riisnaes, Ruth
    Altavilla, Amelia
    Crespo, Mateus
    Tunariu, Nina
    de Bono, Johann S.
    Attard, Gerhardt
    EUROPEAN UROLOGY, 2014, 65 (02) : 270 - 273
  • [46] Satraplatin for the therapy of castration-resistant prostate cancer
    Sonpavde, Guru
    Sternberg, Cora N.
    FUTURE ONCOLOGY, 2009, 5 (07) : 931 - 940
  • [47] Leading causes of castration-resistant prostate cancer
    Lu, Mingqian
    Lu, Hongda
    Kong, Qingzhi
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (04) : 425 - 432
  • [48] Effect of dutasteride on castration-resistant prostate cancer
    Azuma, Takeshi
    Matayoshi, Yukihide
    Sato, Yujiro
    Nagase, Yasuhi
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 8 (01) : 133 - 136
  • [49] PARP inhibition in castration-resistant prostate cancer
    Nappi, Lucia
    Gleave, Martin E.
    FUTURE ONCOLOGY, 2016, 12 (05) : 577 - 580
  • [50] Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer
    Smith, Matthew R.
    Mehra, Maneesha
    Nair, Sandhya
    Lawson, Joe
    Small, Eric J.
    CLINICAL GENITOURINARY CANCER, 2020, 18 (02) : E180 - E189
12345